AmCAD-UO, 10-minute AI-enabled Solution for OSA Assessment

AmCAD-UO, 10-minute AI-enabled Solution for OSA Assessment

AI-driven Diagnostics

Information

AmCAD-UO is the world first ultrasound AI that designed to enhance the evaluation and treatment of obstructive sleep apnea (OSA). This cutting-edge system leverages AI-driven imaging technology to provide rapid insights into patients' upper airway anatomy in 10 minutes, empowering healthcare professionals to make informed decisions with confidence. AmCAD-UO empowers physicians with patient-specific data in making personalized treatments e.g. Mandibular Advancement Device (MAD) and Hypoglossal Nerve Stimulation (HGS).
AmCad BioMed CorporationS7.B98AmCad BioMed, founded in 2008 and listed on the Taipei Exchange (Ticker: 4188), specializes in AI-powered ultrasound solutions that support early and accurate diagnosis. We develop patented ultrasound AI technologies that help doctors detect diseases faster and interpret images with greater consistency. Headquartered in Taiwan, AmCad holds multiple FDA and CE certifications and continues to advance medical imaging through real-world innovation. We are committed to responsible growth, with strong investments in R&D and a focus on ESG principles across our operations.

Log in

See all the content and easy-to-use features by logging in or registering!